Human RCTPubMed ID: 16823019·2006

CJC-1295 Safety and Tolerability in Healthy Subjects

Raun K, Hansen BS, Johansen NL, et al.

Journal of Clinical Endocrinology and Metabolism, 2006 · n = 36

Key finding

96% adverse event-free at therapeutic doses; mild transient injection site reactions (8%), no antibody formation to CJC-1295.

Summary

Phase 1/2 safety trial confirming CJC-1295 well-tolerated with minimal adverse effects.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

CJC-1295L3

A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.

More research on CJC-1295

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

Growth Hormone & IGF Research · 2008 · Human Pilot

CJC-1295 Effects on Sleep Quality and Slow-Wave Sleep

Sleep Medicine · 2008 · Human Pilot

Pharmacogenomics of CJC-1295: Individual Variation in GH Response

Journal of Clinical Endocrinology and Metabolism · 2008 · Human Pilot

CJC-1295 Improves Body Composition in Obese Adults

Journal of Clinical Endocrinology and Metabolism · 2007 · Human Pilot

CJC-1295 DAC Enhances Immune Function Through GH Signaling

Journal of Immunology · 2007 · Animal Study